Most small molecule therapies target G-protein coupled receptors, commonly known as GPCRs. Roughly 34% of all FDA-approved drugs act on these cell-surface receptors, making them the single largest target class for small molecule drugs. Beyond GPCRs, the remaining landscape splits across enzyme inhibitors (especially kinase inhibitors), ion channels, and nuclear receptors.
Why GPCRs Dominate
GPCRs are proteins embedded in cell membranes that relay signals from outside the cell to its interior. They control an enormous range of bodily functions: heart rate, mood, pain perception, immune responses, digestion, and more. That breadth makes them natural drug targets. Currently, 475 FDA-approved drugs act on 108 unique GPCRs, according to an analysis in Nature Reviews Drug Discovery. Many everyday medications fall into this group, including common treatments for high blood pressure, allergies, depression, and asthma.
Small molecules are well suited to GPCRs because their compact size (generally under 900 Daltons in molecular weight) lets them slip into the binding pockets on these receptors. They can either activate or block the receptor depending on the therapeutic goal, which gives drug designers a lot of flexibility.
Enzyme Inhibitors Are the Fastest-Growing Class
While GPCRs hold the overall lead, enzyme inhibitors have become the dominant category in newer drug approvals, particularly in cancer treatment. Among FDA-approved small molecule cancer drugs, selective kinase inhibitors make up the largest group. By August 2022, 88 small molecule inhibitors had been approved specifically for oncology, and kinase inhibitors accounted for the biggest share of that total.
Kinases are enzymes that act as molecular switches, turning cellular processes on and off by adding chemical tags to proteins. In cancer, kinases often get stuck in the “on” position, driving uncontrolled cell growth. Small molecule kinase inhibitors block that activity. Other enzyme targets include proteases (enzymes that break down proteins) and enzymes involved in epigenetic regulation, which controls how genes are read without changing the DNA itself.
The growth of enzyme inhibitors reflects a broader shift in drug development toward precision medicine. Rather than broadly activating or blocking a receptor, these drugs zero in on a specific malfunctioning enzyme within a disease pathway.
Ion Channels and Nuclear Receptors
Ion channels and nuclear receptors round out the major target classes for small molecule drugs. Ion channel drugs account for about 15% of approved therapies, while nuclear receptor drugs make up around 13%. Ion channels are pore-like proteins that control the flow of charged particles in and out of cells. Drugs targeting them are especially common in neurology and cardiology, where electrical signaling is central to organ function.
Nuclear receptors sit inside cells and directly influence gene activity when activated. They are important targets for hormonal therapies and metabolic conditions. Interestingly, while nuclear receptor drugs represent 17% of treatments for conditions outside the nervous system, none have been approved for neurological disorders. This isn’t because nuclear receptors are unimportant in the brain. Rather, the molecules that bind nuclear receptors tend to be larger and more fat-soluble, making it harder for them to cross the blood-brain barrier effectively.
How Small Molecules Compare to Biologics
Small molecules remain the backbone of the pharmaceutical market, though biologics (large, complex molecules like antibodies) are a growing share. In 2024, the FDA approved 50 novel drugs total, a mix of small molecule new molecular entities and biologic therapies. Small molecules still hold key advantages: they can typically be taken as pills rather than injections, they’re cheaper to manufacture, and their small size lets them reach targets inside cells that larger biologic molecules cannot access.
That intracellular access is exactly why small molecules dominate the GPCR, enzyme, ion channel, and nuclear receptor categories. Biologics, by contrast, excel at hitting targets on the outside of cells or circulating in the bloodstream. The two approaches are complementary, but for the vast majority of drug targets that sit within or on the surface of cells, small molecules remain the go-to tool.
The Breakdown at a Glance
- GPCRs: ~34% of all FDA-approved drugs, the largest single target class
- Ion channels: ~15% of approved drugs, especially important in neurology and heart conditions
- Nuclear receptors: ~13% of approved drugs, central to hormonal and metabolic therapies
- Enzyme inhibitors (especially kinases): the fastest-growing class, dominating recent cancer drug approvals
These four categories collectively account for the overwhelming majority of small molecule therapies on the market. GPCRs lead in total numbers, but if you look only at drugs approved in the last decade, enzyme inhibitors, particularly kinase inhibitors in oncology, have been gaining ground rapidly.